TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy
Brief Summary: The purpose of this study is to compare the effectiveness of treating acute ischemic stroke with mechanical embolectomy using the Merci Retriever or the Penumbra System within 8 hours of symptom onset to standard medical treatment, and to identify people who might benefit from mechanical embolectomy by the appearance of stroke on multimodal computerized tomography (CT) or magnetic resonance (MR) imaging.


Options:
A: Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard medical therapy | Arm Label: endovascular + standard medical therapy; Type: EXPERIMENTAL; Interventions: Device: endovascular treatment, Other: standard medical therapy | Intervention Type: DEVICE; Name: endovascular treatment; Assigned to Arm(s): endovascular + standard medical therapy | Intervention Type: OTHER; Name: standard medical therapy; Assigned to Arm(s): endovascular + standard medical therapy, standard medical therapy
B: Arm Label: Best standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Best standard treatment | Arm Label: Mechanical thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: mechanical thrombectomy | Intervention Type: PROCEDURE; Name: mechanical thrombectomy; Assigned to Arm(s): Mechanical thrombectomy | Intervention Type: DRUG; Name: Best standard treatment; Assigned to Arm(s): Best standard treatment
C: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy
D: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy
Brief Summary: The purpose of this study is to compare the effectiveness of treating acute ischemic stroke with mechanical embolectomy using the Merci Retriever or the Penumbra System within 8 hours of symptom onset to standard medical treatment, and to identify people who might benefit from mechanical embolectomy by the appearance of stroke on multimodal computerized tomography (CT) or magnetic resonance (MR) imaging.


Options:
A: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA
B: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
D: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Order in Which Vaccines Are Administered Affect Pain Response? A Randomized, Double-blind, Clinical Trial of Pentacel vs. Prevnar
Brief Summary: The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.


Options:
A: Intervention Type: PROCEDURE; Name: Percutaneous Suprapubic Aspiration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Urethral Catheterization; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: pillow | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pillow; Assigned to Arm(s): 1
C: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar
D: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Order in Which Vaccines Are Administered Affect Pain Response? A Randomized, Double-blind, Clinical Trial of Pentacel vs. Prevnar
Brief Summary: The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.


Options:
A: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B: Music; Type: EXPERIMENTAL; Interventions: Other: Music | Intervention Type: OTHER; Name: Music; Assigned to Arm(s): Group B: Music
B: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Educational Video - Sham, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose Placebo (water), Drug: Lidocaine Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational video - Active, Drug: Sucrose, Drug: Lidocaine | Intervention Type: BEHAVIORAL; Name: Educational video - Active; Assigned to Arm(s): Group 2, Group 3, Group 4 | Intervention Type: BEHAVIORAL; Name: Educational Video - Sham; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Sucrose Placebo (water); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Lidocaine Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3 | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Group 4
C: Arm Label: Standard intervention; Type: SHAM_COMPARATOR; Interventions: Other: standard | Arm Label: clown care; Type: EXPERIMENTAL; Interventions: Behavioral: clown care | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): Standard intervention | Intervention Type: BEHAVIORAL; Name: clown care; Assigned to Arm(s): clown care
D: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients
Brief Summary: This study will compare three standard treatment programs commonly offered to patients with breast cancer. The three programs being compared are 1) Mindfulness Meditation-Based Stress Reduction (MBSR), 2)Supportive- Expressive Group Therapy (SET), and 3) A one day stress-management seminar. The purpose of this study is to determine if these three treatments have different effects on psychological well-being, the immune system, and the amount of stress hormones in the bloodstream.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eribulin Mesylate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Eribulin Mesylate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 2
B: Arm Label: Mindfulness-Based Cognitive Therapy (MBCT); Type: EXPERIMENTAL; Interventions: Other: Mindfulness-Based Cognitive Therapy | Arm Label: Waitlist control group; Type: OTHER; Interventions: Other: Waitlist | Intervention Type: OTHER; Name: Mindfulness-Based Cognitive Therapy; Assigned to Arm(s): Mindfulness-Based Cognitive Therapy (MBCT) | Intervention Type: OTHER; Name: Waitlist; Assigned to Arm(s): Waitlist control group
C: Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: Mindfulness Meditation-Based Stress Reduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive-Expressive Group Therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients
Brief Summary: This study will compare three standard treatment programs commonly offered to patients with breast cancer. The three programs being compared are 1) Mindfulness Meditation-Based Stress Reduction (MBSR), 2)Supportive- Expressive Group Therapy (SET), and 3) A one day stress-management seminar. The purpose of this study is to determine if these three treatments have different effects on psychological well-being, the immune system, and the amount of stress hormones in the bloodstream.


Options:
A: Arm Label: Nurse-led care; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led care, Behavioral: Routine care | Arm Label: Routine care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Routine care | Intervention Type: BEHAVIORAL; Name: Nurse-led care; Assigned to Arm(s): Nurse-led care | Intervention Type: BEHAVIORAL; Name: Routine care; Assigned to Arm(s): Nurse-led care, Routine care
B: Intervention Type: BEHAVIORAL; Name: Group Therapy Intervention; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Mindfulness Meditation-Based Stress Reduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive-Expressive Group Therapy; Assigned to Arm(s): N/A
D: Arm Label: MBSR 6 Weeks Program; Type: EXPERIMENTAL; Interventions: Behavioral: MBSR 6 Weeks Program | Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MBSR 6 Weeks Program; Assigned to Arm(s): MBSR 6 Weeks Program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The primary objective of this study is to determine whether DAC HYP, when compared to placebo, is effective in reducing the rate of relapses between baseline and Week 52. The secondary objectives are to determine whether DAC HYP is effective in reducing the number of new gadolinium (Gd)-enhancing lesions, reducing the number of new or newly-enlarging T2 hyperintense lesions, reducing the proportion of participants with relapses, and improving quality of life.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: OMG 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
C: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
D: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The primary objective of this study is to determine whether DAC HYP, when compared to placebo, is effective in reducing the rate of relapses between baseline and Week 52. The secondary objectives are to determine whether DAC HYP is effective in reducing the number of new gadolinium (Gd)-enhancing lesions, reducing the number of new or newly-enlarging T2 hyperintense lesions, reducing the proportion of participants with relapses, and improving quality of life.


Options:
A: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
B: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet, Obesity and Genes
Brief Summary: Study Title: Diogenes, A randomised controlled trial comparing the effect of reduced-fat diets varying in glycaemic index (high vs. low) and protein content (high vs. normal) on bodyweight in overweight and obese subjects after an initial weight loss.


Options:
A: Intervention Type: BEHAVIORAL; Name: high protein & low glycemic index diets; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: Low glycemic load dietary plan; Type: EXPERIMENTAL; Interventions: Behavioral: Low Glycemic Load Diet versus Low Fat Diet | Arm Label: Low fat diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Glycemic Load Diet versus Low Fat Diet | Intervention Type: BEHAVIORAL; Name: Low Glycemic Load Diet versus Low Fat Diet; Assigned to Arm(s): Low fat diet, Low glycemic load dietary plan
D: Intervention Type: BEHAVIORAL; Name: low glycemic load diet; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: low fat diet; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet, Obesity and Genes
Brief Summary: Study Title: Diogenes, A randomised controlled trial comparing the effect of reduced-fat diets varying in glycaemic index (high vs. low) and protein content (high vs. normal) on bodyweight in overweight and obese subjects after an initial weight loss.


Options:
A: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
B: Arm Label: Podcasting + mobile media; Type: EXPERIMENTAL; Interventions: Behavioral: Podcasting + mobile media | Arm Label: Podcasting; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Podcasting + mobile media | Intervention Type: BEHAVIORAL; Name: Podcasting + mobile media; Assigned to Arm(s): Podcasting, Podcasting + mobile media
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Modification | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Lifestyle Modification | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Modification; Assigned to Arm(s): Group 2, Group 4

Answer: C